Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

697 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India.
Sinha S, N K, Suram VK, Chary SS, Naik S, Singh VB, Jain MK, Suthar CP, Borthakur S, Sawardekar V, Sk N, Reddy N, Talluri L, Thakur P, Reddy M, Panapakam M, Vattipalli R. Sinha S, et al. Among authors: jain mk. Cureus. 2022 Nov 14;14(11):e31508. doi: 10.7759/cureus.31508. eCollection 2022 Nov. Cureus. 2022. PMID: 36532902 Free PMC article.
Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPD.
Salvi S, Jain MK, Krishnamurthy S, Balki A, Kodgule R, Tandon M, Bhagat S, Panchal S, Khatri N, Wu W, Pendse A, Patil S, Barkate H. Salvi S, et al. Among authors: jain mk. Lung India. 2022 Nov-Dec;39(6):517-524. doi: 10.4103/lungindia.lungindia_136_22. Lung India. 2022. PMID: 36629230 Free PMC article.
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
Saraf A, Gurjar R, Kaviraj S, Kulkarni A, Kumar D, Kulkarni R, Virkar R, Krishnan J, Yadav A, Baranwal E, Singh A, Raghuwanshi A, Agarwal P, Savergave L, Singh S; GEMCOVAC-OM Study Investigators. Saraf A, et al. Nat Med. 2024 May;30(5):1363-1372. doi: 10.1038/s41591-024-02955-2. Epub 2024 Apr 18. Nat Med. 2024. PMID: 38637636 Free PMC article. Clinical Trial.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Dayan GH, et al. Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. Lancet Respir Med. 2023. PMID: 37716365 Free PMC article. Clinical Trial.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kaali S, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Uchiyama A, Sawe F, Schuerman L, Shrestha R, Tong T, Treanor J, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 study team. Dayan GH, et al. EClinicalMedicine. 2023 Sep 12;64:102168. doi: 10.1016/j.eclinm.2023.102168. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37936652 Free PMC article.
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.
O'Hara DV, Bassi A, Wilcox A, Jha V, Rathore V, D'Cruz S, Snelling TL, Jones M, Totterdell J, Bangi A, Jain MK, Pollock C, Burrell L, Fox G, Jones C, Kotwal S, Faridah Syed Omar S, Jardine M; CLARITY 2.0 trial investigators. O'Hara DV, et al. Among authors: jain mk. BMJ Open. 2024 Oct 22;14(10):e081790. doi: 10.1136/bmjopen-2023-081790. BMJ Open. 2024. PMID: 39438096 Free PMC article. Clinical Trial.
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®).
Singh C, Verma S, Reddy P, Diamond MS, Curiel DT, Patel C, Jain MK, Redkar SV, Bhate AS, Gundappa V, Konatham R, Toppo L, Joshi AC, Kushwaha JS, Singh AP, Bawankule S, Ella R, Prasad S, Ganneru B, Chiteti SR, Kataram S, Vadrevu KM. Singh C, et al. Among authors: jain mk. NPJ Vaccines. 2023 Aug 18;8(1):125. doi: 10.1038/s41541-023-00717-8. NPJ Vaccines. 2023. PMID: 37596281 Free PMC article.
Colchicine to reduce coronavirus disease-19-related inflammation and cardiovascular complications in high-risk patients post-acute infection with SARS-COV-2-a study protocol for a randomized controlled trial.
Thankachen SS, Devasenapathy N, Bassi A, Ghosh A, Arfin S, Gummidi B, Basheer A, Bangi A, Sahu D, Bhalla A, Blesson M, Jain M, Jha V. Thankachen SS, et al. Trials. 2024 Jun 12;25(1):378. doi: 10.1186/s13063-024-08205-7. Trials. 2024. PMID: 38863076 Free PMC article.
697 results